Supply chain visibility ensuring authenticity of drugs

As part of the C4CS initiative, all the partners performed a research, aimed to create ReferenceModels (supply chain simulations), to explore the use of blockchain technology within the pharmaceutical supply chain for the purposes of meeting year 2023 obligations of the DSCSA in phase 1 of the initiative. Now, under the Phase 2 of the initiative, proof of concept pilots study will be conducted to build on that body of knowledge to take the ReferenceModels out of simulation and into limited pilots using actual blockchain technology.

Company

Pfizer

Merck & Co.

Cardinal Health

AmerisourceBergen Corp

Geisinger health system

Healthcare Distribution Alliance

Rx-360

iSolve

TraceLink

Unisys

Verify Brand

Status

In process

Tags
  • Drug Supply Chain
  • Pharma
  • Pharma distributors
  • Provider
  • Health Alliances/Consortiums
  • Tech
supply-chain-referencemodel.jpeg
supply-chain-referencemodel-1.jpeg
supply-chain-referencemodel-2.jpeg
supply-chain-referencemodel-3.jpeg
supply-chain-referencemodel-4.jpeg
supply-chain-referencemodel-5.jpeg

Problem statement

Establishing trust between trading partners and compliance with the US Drug Supply Chain Security Act (DSCSA).

Approach

The team created and evaluated various simulated supply chain scenarios (ReferenceModels) that helped to visualize the results.

Technical details

A simulated environment was created that allowed the team to test certain hypotheses. The results of the simulations and the data generated are known as ReferenceModels. Below are the three ReferenceModels:

  • ReferenceModel 1: Stocks the complete Transaction Information (TI) in a shared blockchain platform for retrieval. Also, transact Electronic Product Code Information Services (EPCIS) events straight between trading partners to connect the contents of shipments and logistics units.
  • ReferenceModel 2: Stocks address to trading partner portals/repositories of Transaction Information (TI) for recovery in an industry-shared blockchain platform. Also, transact EPCIS events staright between trading partners to communicate the contents of shipments and logistics units.
  • ReferenceModel 3: Send DSCSA Transaction Information (TI) to blockchain platform distributed applications (DApps) that assess the data and store present “states” of the individual Product identifier. An enlarges version comprises of shipment hierarchy and may reduce the need to transact EPCIS events directly between trading partners.

As supply chain stakeholders are currently working through serialization of drug products, there are not enough of them to fully pilot any of the ReferenceModel designs. The next steps are to move from a simulated environment to test environments where the technology can be explored using test or simulated data. Once the stakeholders begin to converge on single model and can engage in connecting internal systems to a test environment, full pilots and implementations will follow.

Published white paper for study findings

Presented

IEEE Blockchain for the Pharma Supply Chain Forum 2017

Presented

Cold Chain Global Forum Annual 18

Presented

FutureLink 2018

Presented

{"Distributed"=>"Health 2018"}

Presented

2018 Blockchain Healthcare Forum

Presented

{"Interphex 2018"=>"PharmaTech Keynote Series"}

Presented

{"Symposium"=>"World of supply chain management 2018, Rider University"}

Presented